Difference between revisions of "Marginal zone lymphoma - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. " to "") |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
| − | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only | + | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? Please go to the [[Marginal zone lymphoma|main MZL regimen page]] to find other regimens. |
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
| Line 26: | Line 26: | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
| − | *[[Umbralisib (Ukoniq)]] 800 mg PO once per day on days 1 to 28, with food | + | *[[Umbralisib (Ukoniq)]] 800 mg PO once per day on days 1 to 28, taken with food |
'''28-day cycles''' | '''28-day cycles''' | ||
Latest revision as of 11:21, 13 May 2024
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? Please go to the main MZL regimen page to find other regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Umbralisib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Fowler et al. 2021 (UNITY-NHL) | 2017-2018 | Phase 2b (RT) |
Targeted therapy
- Umbralisib (Ukoniq) 800 mg PO once per day on days 1 to 28, taken with food
28-day cycles
References
- UNITY-NHL: Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02793583